MRVI Historical PE Ratio Notes

— Maravai LifeSciences Holdings, Inc. (MRVI) is a life sciences company specializing in products & services that enable the development of cutting-edge therapeutics, diagnostics, and vaccines. Its core offerings include nucleic acid production (especially mRNA and related raw materials), bioprocess impurity detection tools, and protein labeling reagents, serving pharmaceutical, biotechnology, and academic sectors. Maravai’s business surged during the COVID-19 pandemic, as its mRNA capabilities became critical to vaccine makers, notably supplying CleanCap reagents for Pfizer-BioNTech’s COVID-19 vaccine. As you examine MRVI’s historical P/E ratio, keep in mind that during pandemic years (2020-2022), both revenue & earnings experienced extraordinary spikes, leading to potentially lower P/E ratios during that period due to supernormal profits. As global vaccine demand has normalized, Maravai’s earnings have reset, and investors' expectations for future growth have shifted, directly impacting the P/E ratio. Fluctuations you see in these historical charts are tightly linked to the cyclicality driven by pandemic-driven demand spikes & their subsequent normalization—factors that are crucial context for interpreting MRVI’s valuation history.

On this page we presented the Maravai LifeSciences Historical PE Ratio information for Maravai LifeSciences' stock. The average MRVI historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 46.4. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average MRVI historical PE based on this TTM earnings result method is 30.8. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this MRVI historical PE result, against the recent PE: when this page was posted on 6/4/2026, the most recent closing price for MRVI had been 4.99, and the most recent quarterly earnings result, annualized, was 0.04. Meanwhile, the most recent TTM earnings summed to 0.03. From these numbers, we calculate the recent MRVI PE on 6/4/2026 based on annualized quarterly EPS was 124.8. Based on MRVI's history, that recent PE is elevated relative to the historical average, with the recent PE 169.0% higher than the historical average PE across our data set for Maravai LifeSciences. Looking at the recent MRVI PE on 6/4/2026 based on TTM EPS, we calculate the ratio at 166.3. Based on MRVI's history, that recent PE is elevated relative to the historical average, with the recent PE 439.9% higher than the historical average PE across our Maravai LifeSciences data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on MRVI or any other given stock, valuation analysis for MRVI can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Maravai LifeSciences PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for MRVI. Thanks for visiting, and the next time you need to research MRVI Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.